10-hydroxycamptothecin has been researched along with Cancer of Ovary in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alloatti, D; Badaloni, E; Cabri, W; Castorina, M; Giannini, G; Pisano, C; Vesci, L | 1 |
| Bai, J; Bian, Z; Chen, F; Fu, S; Guan, R; Jin, Y; Quan, C; Sun, W; Wu, J; Xu, L; Yu, Y | 1 |
| Shen, K; Sun, Z; Xu, X | 1 |
3 other study(ies) available for 10-hydroxycamptothecin and Cancer of Ovary
| Article | Year |
|---|---|
Camptothecins in tumor homing via an RGD sequence mimetic.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Integrins; Male; Oligopeptides; Ovarian Neoplasms; Prostatic Neoplasms; Rats | 2012 |
RPL13A as a reference gene for normalizing mRNA transcription of ovarian cancer cells with paclitaxel and 10-hydroxycamptothecin treatments.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Computational Biology; Female; Gene Expression Profiling; Humans; Ovarian Neoplasms; Paclitaxel; Ribosomal Proteins; RNA Stability; RNA, Messenger; Transcription, Genetic | 2015 |
[The effect of hydroxycamptothecin and topotecan to SKOV3 and CAOV3 in vitro].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured | 1999 |